Research Topics
| Shiling HuSummaryAffiliation: Novartis Institutes for BioMedical Research Publications
| Collaborators
|
Detail Information
Publications
Inhibition of delayed rectifier K+ channels by dexfenfluramine (Redux)S Hu
Research Department, Novartis Pharmaceuticals Corp, Summit, New Jersey, USA
J Pharmacol Exp Ther 287:480-6. 1998..The common inhibitory effect on DRK channels in oral taste cells and cardiac cells by this class of compounds might contribute to the anorectic and some of the detrimental cardiovascular effect associated with long-term exposure...- Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cellS Hu
Metabolic Cardiovascular Diseases, Novartis Institute for Biomedical Research, 556 Morris Avenue, Summit, NJ 07901, USA
Eur J Pharmacol 427:97-104. 2001..The direct effects of these antidiabetic agents on Kv and Ca(2+) channels may act concertedly with their primary action on K(ATP) channels in regulating [Ca(2+)](i) and the stimulus-secretion coupling... - Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic actionShiling Hu
Metabolic Cardiovascular Diseases, Research Department, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
Eur J Pharmacol 442:163-71. 2002..The data provide mechanistic rationale for the unique in vivo and ex vivo activity profile of nateglinide and may contribute to reduced hypoglycemic potential associated with excessive insulin secretion... 
Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinideS Hu
Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
Int J Exp Diabetes Res 2:63-72. 2001..Further, the present findings suggest that nateglinide may exert a more physiologic effect on insulin secretion than comparator agents and thereby have less propensity to elicit hypoglycemia in vivo...- Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureasS Hu
Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
Int J Exp Diabetes Res 2:73-9. 2001..The insulinotropic efficacy of NAT in islets desensitized to SUs may result from a distinct receptor/effector mechanism, which contributes to the unique pharmacological profile of NAT... - The mechanisms underlying the unique pharmacodynamics of nateglinideS Hu
Novartis Institute for Biomedical Research, 556 Morris Avenue, LSB 2287 Summit, NJ 07901, USA
Diabetologia 46:M37-43. 2003..Given that the kinetic profile of the agent is associated with selective enhancement of early-phase insulin secretion, nateglinide is expected to minimise post-meal hyperglycaemia with minimal propensity for hypoglycaemia... - Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinideS Hu
Metabolic and Cardiovascular Disease Department, Novartis Institute for Biomedical Research, Summit, New Jersey 07901, USA
J Pharmacol Exp Ther 293:444-52. 2000..These results suggest that the unique characteristics of nateglinide are largely the result of its interaction at the K(ATP) channel... - Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channelsS Hu
Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, New Jersey 07901 1027, USA
J Pharmacol Exp Ther 291:1372-9. 1999..These data collectively indicate that NAT, when compared with GLY and REP, at concentrations effective in stimulating insulin secretion is least likely to cause detrimental CV effects via blockade of CV K(ATP) channels... - Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720Fumin Fu
Novartis Institute for Biomedical Research, Summit, New Jersey; Novartis Pharma AG, Basel, Switzerland
Transplantation 73:1425-30. 2002..The effect is likely attributable to its action in preventing effector lymphocyte infiltration into the grafted tissue...